Metabolic Surgery for Atrial Fibrillation Elimination
Status:
NOT_YET_RECRUITING
Trial end date:
2029-03-31
Target enrollment:
Participant gender:
Summary
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia. It is estimated that between 3 and 6 million Americans are currently living with AF, while 12 million people in the United States will have AF in 2030. Obesity and its comorbidities such as type 2 diabetes (T2DM), hypertension, and obstructive sleep apnea (OSA) are major risk factors for development and progression of AF. Metabolic and Bariatric Surgery (MBS) is the most effective currently available treatment for obesity. Patients typically lose 20 to 35 percent of body weight after surgery which is often sustained for many years. MBS can improve all 5 major risk factors of AF including obesity, hypertension, T2DM, OSA, and systemic inflammation.
The purpose of the study is to understand if MBS can affect the severity of AF and the toll AF's symptoms take on patients.
Phase:
PHASE4
Details
Lead Sponsor:
Ali Aminian
Collaborators:
Ethicon, Inc. iRhythm Technologies, Inc.
Treatments:
Bariatric Surgery Collagen Type II Gastric Bypass Therapeutics